INmune Bio Inc’s recently made public that its Director Juda Scott acquired Company’s shares for reported $48650.0 on Nov 10 ’23. In the deal valued at $6.95 per share,7,000 shares were bought. As a result of this transaction, Juda Scott now holds 37,000 shares worth roughly $0.39 million.
Then, Schroeder Timothy j sold 10,000 shares, generating $110,085 in total proceeds. Upon selling the shares at $11.01, the Director now owns 82,187 shares.
Robert W. Baird initiated its INmune Bio Inc [INMB] rating to an Outperform in a research note published on June 01, 2023; the price target was $16. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who decreased its forecast for the stock in late May from “a Buy” to “a Neutral”. Maxim Group also remained covering INMB and reiterated its “Buy” recommendation on July 07, 2021. B. Riley Securities started covering the stock on April 21, 2021. It rated INMB as “a Buy”.
Price Performance Review of INMB
On Monday, INmune Bio Inc [NASDAQ:INMB] saw its stock jump 26.94% to $10.62. Over the last five days, the stock has gained 10.91%. INmune Bio Inc shares have fallen nearly -5.64% since the year began. Nevertheless, the stocks have risen 33.65% over the past one year. While a 52-week high of $14.74 was reached on 02/14/24, a 52-week low of $6.50 was recorded on 04/19/24. SMA at 50 days reached $11.54, while 200 days put it at $9.61. A total of 0.68 million shares were traded, compared to the trading of 69200.0 shares in the previous session.
Levels Of Support And Resistance For INMB Stock
The 24-hour chart illustrates a support level at 9.11, which if violated will result in even more drops to 7.59. On the upside, there is a resistance level at 11.44. A further resistance level may holdings at 12.25. The Relative Strength Index (RSI) on the 14-day chart is 51.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 23.27%. Stochastics %K at 30.32% indicates the stock is a holding.
The most recent change occurred on January 22, 2021 when Maxim Group resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $32.
